Ranbaxy Labs Mulls Testing Unit Spin-off (India)
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories Ltd, India's second largest drugmaker, has invested heavily in research and development (R&D). The company is considering options such as spinning off the testing and development services part of its R&D facility into a separate company and partnering a leading clinical trials firm. Ranbaxy "is in talks with a few multinational players in the drug development business to set up a joint venture company that will undertake development services of Ranbaxy as well as similar projects from outside," according to an unidentified person familiar with the situation. Another proposed option is to expand Ranbaxy's partnership model in core drug discovery research. Ranbaxy signed a multi-year agreement with global drug maker GlaxoSmithKline Plc. for drug discovery research earlier this year, and hopes to forge similar partnerships with other firms. "This will help reducing dependence on the parent company to sustain high-cost R&D and will also optimize utilization of the already created infrastructure," the person said. Ranbaxy's off-patent or generic drugs R&D pipeline has about 88 drug applications pending with the FDA, approximately 20 first-to-file generic drug candidates that can be commercialized soon, and four new drug compounds at various development stages. (Click here for more
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.